Prevalence of Respiratory Disorders during Sleep among Subjects of Methadone Maintenance Therapy Program.
Apnea
Opiate substitution treatment
Respiration disorders
Substance-related disorders
Journal
Addiction & health
ISSN: 2008-4633
Titre abrégé: Addict Health
Pays: Iran
ID NLM: 101582275
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
22
02
2021
accepted:
27
04
2021
entrez:
10
2
2022
pubmed:
11
2
2022
medline:
11
2
2022
Statut:
ppublish
Résumé
Respiratory disorders during sleep are considered a health problem affecting the life quality. There is some evidence indicating the higher prevalence of apnea in substance-dependent patients. However, there is no information on the prevalence of the disease in people under methadone maintenance therapy (MMT). Therefore, the present study was designed to estimate the disease rate in these patients and consider the relationship of the increasing risk of apnea with some psychiatric problems. Study group included 152 individuals under the MMT program. Baseline data were collected with the interview, and patients were considered using the STOP-BANG questionnaire to evaluate the risk of apnea. Furthermore, Epworth Sleepiness Scale (ESS), Fatigue Severity Scale (FSS), Hamilton Anxiety Rating Scale (HAM-A), and Hamilton Depression Rating Scale (HDRS) tests were performed for all participants. Data were analyzed using SPSS software. Based on the STOP-BANG score categories, 37.5%, 40.1%, and 22.4% of patients indicated low, intermediate, and high risk of apnea, respectively. Moreover, severe daytime sleepiness, fatigue, depression, and anxiety were observed in 5.3%, 5.5%, 6.0%, and 21.1% of participants, respectively. Sex (P = 0.007) and daytime sleepiness (P = 0.048) were significantly different between low and high-risk groups of apnea after adjustment. Besides, age (P < 0.001) and fatigue (P = 0.007) were factors predicting the STOP-BANG score. These findings revealed the higher prevalence of apnea in MMT patients compared to the general population of Iran and rising of the risk of apnea along with an increase in age and fatigue score. However, attention to the sleep disorders in MMT is a prominent factor that should be considered as a route of therapy.
Sections du résumé
BACKGROUND
BACKGROUND
Respiratory disorders during sleep are considered a health problem affecting the life quality. There is some evidence indicating the higher prevalence of apnea in substance-dependent patients. However, there is no information on the prevalence of the disease in people under methadone maintenance therapy (MMT). Therefore, the present study was designed to estimate the disease rate in these patients and consider the relationship of the increasing risk of apnea with some psychiatric problems.
METHODS
METHODS
Study group included 152 individuals under the MMT program. Baseline data were collected with the interview, and patients were considered using the STOP-BANG questionnaire to evaluate the risk of apnea. Furthermore, Epworth Sleepiness Scale (ESS), Fatigue Severity Scale (FSS), Hamilton Anxiety Rating Scale (HAM-A), and Hamilton Depression Rating Scale (HDRS) tests were performed for all participants. Data were analyzed using SPSS software.
FINDINGS
RESULTS
Based on the STOP-BANG score categories, 37.5%, 40.1%, and 22.4% of patients indicated low, intermediate, and high risk of apnea, respectively. Moreover, severe daytime sleepiness, fatigue, depression, and anxiety were observed in 5.3%, 5.5%, 6.0%, and 21.1% of participants, respectively. Sex (P = 0.007) and daytime sleepiness (P = 0.048) were significantly different between low and high-risk groups of apnea after adjustment. Besides, age (P < 0.001) and fatigue (P = 0.007) were factors predicting the STOP-BANG score.
CONCLUSION
CONCLUSIONS
These findings revealed the higher prevalence of apnea in MMT patients compared to the general population of Iran and rising of the risk of apnea along with an increase in age and fatigue score. However, attention to the sleep disorders in MMT is a prominent factor that should be considered as a route of therapy.
Identifiants
pubmed: 35140895
doi: 10.22122/ahj.v13i3.311
pii: AHJ-13-176
pmc: PMC8730449
doi:
Types de publication
Journal Article
Langues
eng
Pagination
176-184Informations de copyright
© 2021 Kerman University of Medical Sciences.
Références
Rev Environ Health. 2019 Jun 26;34(2):153-169
pubmed: 31085749
Addict Health. 2012 Winter-Spring;4(1-2):1-8
pubmed: 24494130
Arch Neurol. 1989 Oct;46(10):1121-3
pubmed: 2803071
Psychiatry (Edgmont). 2009 Sep;6(9):38-42
pubmed: 19855859
Sleep. 1992 Aug;15(4):376-81
pubmed: 1519015
Acad Forensic Pathol. 2017 Mar;7(1):19-35
pubmed: 31239953
Neuropsychiatr Dis Treat. 2018 Oct 26;14:2853-2859
pubmed: 30464470
Qual Life Res. 2015 Aug;24(8):2025-30
pubmed: 25613199
Tanaffos. 2017;16(3):217-224
pubmed: 29849675
Psychiatry Res. 2017 Dec;258:177-183
pubmed: 28774662
Med Clin North Am. 2018 Jul;102(4):733-743
pubmed: 29933826
J Clin Sleep Med. 2013 Oct 15;9(10):997-1002
pubmed: 24127143
Int Rev Psychiatry. 2014 Apr;26(2):237-47
pubmed: 24892898
Subst Abuse Treat Prev Policy. 2017 Mar 20;12(1):16
pubmed: 28320448
Nat Sci Sleep. 2021 May 04;13:537-545
pubmed: 33976579
Addict Health. 2016 Apr;8(2):84-89
pubmed: 27882205
Psychiatry Res. 1994 Aug;53(2):191-202
pubmed: 7824679
J Addict Med. 2008;2(4):194-201
pubmed: 21768990
Int J Occup Environ Med. 2020 Apr;11(2):95-107
pubmed: 32218557
Am J Psychiatry. 2004 Dec;161(12):2163-77
pubmed: 15569884
Addict Sci Clin Pract. 2016 Apr 26;11(1):9
pubmed: 27117064
Anesth Analg. 2015 Jun;120(6):1273-85
pubmed: 25988636
Sleep Breath. 2013 Mar;17(1):419-26
pubmed: 22327509
Lancet Respir Med. 2019 Aug;7(8):687-698
pubmed: 31300334
Appl Psychophysiol Biofeedback. 2016 Mar;41(1):103-10
pubmed: 26392114
Int J Environ Res Public Health. 2019 Nov 06;16(22):
pubmed: 31698771
Br J Anaesth. 2012 May;108(5):768-75
pubmed: 22401881
Anesthesiology. 2008 May;108(5):812-21
pubmed: 18431116
Tanaffos. 2019 Jan;18(1):1-10
pubmed: 31423134
Sleep Breath. 2012 Jun;16(2):375-81
pubmed: 21465092
Psychiatr Clin North Am. 2015 Dec;38(4):793-803
pubmed: 26600109
J Res Med Sci. 2014 Mar;19(3):205-10
pubmed: 24949026
Health Qual Life Outcomes. 2019 Aug 5;17(1):136
pubmed: 31382960